in terms of a buyout, if one was offered to ariad but turned down by the powers to be, would that info have to be disclosed to the public? seems that bit of info would help the share price, regardless of any decision. also, ariads financial situation has made them an easier buyout candidate since the crash. is it possible that even in its weakened state, it just isn't as appealing to a big pharma to approach, as most here think it should be?
News 
Market Data 
Discover 
AI
